Clinical outcomes of hematopoietic stem cell transplantation from HLA-matched parental donor in childhood acute leukemia.
- Author:
Eun Young CHA
1
;
Moon Hee LEE
;
Jae Wook LEE
;
Young Joo KWON
;
Dae Hyoung LEE
;
Young Shil PARK
;
Nak Gyun CHUNG
;
Dae Chul JEONG
;
Bin CHO
;
Hack Ki KIM
Author Information
- Publication Type:Original Article
- Keywords: Acute leukemia; Hematopoietic stem cell transplantation; HLA-matched parent
- MeSH: Blood Platelets; Child; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histocompatibility Testing; Humans; Leukemia; Male; Neutrophils; Parents; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Siblings; Tissue Donors; Transplants
- From:Korean Journal of Pediatrics 2008;51(1):67-72
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: In this study, we retrospectively analyzed the clinical outcomes of patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) grafted from HLA-matched parents. METHODS: Seven children with acute leukemia (4 acute lymphoblastic leukemia, 3 acute myeloid leukemia) in first complete remission received allogeneic HSCT from their respective parents at the St. Marys Hospital between April, 1999 and October, 2005. The median age of patients at transplantation was 5 years (range, 1-11 years; 2 male, 5 female) and the median age of donors was 35 years (range, 30-41 years; 5 male, 2 female). We investigated the clinical outcomes such as engraftment, acute and chronic graft-versus-host disease (GVHD), transplant-related morbidity and mortality, relapse and survival. RESULTS: Median time from transplantation to last follow-up was 69.5 months (range, 18.8-96.5 months). All patients were successfully engrafted, with a median time of 11 days (range, 10-16 days) and 26 days (range, 13-39 days) for neutrophil and platelet recovery, respectively. Grade II acute GVHD occurred in 3, and grade III acute GVHD in 1 of 7 recipients. Extensive chronic GVHD developed in 2, and limited chronic GVHD in 1 of 7 recipients. Death from transplant-related complications occurred in 1, and relapse occurred in 1 of 7 recipients. Estimated 5-year overall survival was 83+/-15%. CONCLUSION: The clinical outcomes of recipients who underwent HSCT from HLA-matched parents were comparable to those of patients who received HSCT grafted from HLA-matched sibling donors in childhood leukemia. HLA typing of parents, as well as siblings will increase the likelihood of finding an HLA-matched family donor for patients who need HSCT.
